Onyx Completes API Project with US Drug Developer
UK-based contract research organisation Onyx Scientific has completed a development and API manufacturing project with US-based Neuronascent, Inc. to support the company with its focus on neurologic disorders.
Neuronascent develops orally available, novel neurogenic and neurorestorative therapeutics that target Parkinson’s disease, Down syndrome, Alzheimer’s disease and post-traumatic stress disorder.
Onyx Scientific assisted the Maryland headquartered firm with the process development and production of a 1-kg batch of API that was used in the pre-IND submission along with supporting with initial stability data.
Neuronascent’s lead candidate is NNI-362, which is aimed at Alzheimer’s and Parkinson’s disease and other neurodegenerative disorders.
Judith Kelleher-Andersson, PhD, founder, president and chief executive officer at Neuronascent said: “Onyx Scientific has the ability to synthesize high quality API, while still taking into account the time and financial concerns of a small biotech company.
“We have had a very positive experience in dealing with the entire Onyx Scientific team and they have played an important role in moving our Alzheimer’s disease project forward.”
With MHRA and FDA facilities in the UK and India, Ipca Laboratories owned Onyx Scientific assists companies from medicinal chemistry and preclinical through Phase I-III, scaling-up to large scale API production.
The CMO has recently enhanced its presence in the US by adding local representation to support west coast clients, which complements the firm’s existing presence on the east coast.
Denise Bowser, commercial director at Onyx Scientific, said: “We thoroughly enjoyed working with the team at Neuronascent and were able to deliver their project on time despite a pretty tight deadline.
“Early-stage development and small-scale manufacture of API has been our sweet spot for many years, but we continue to improve to ensure we are meeting the needs of our clients across the world who are dealing with increased pressure to develop new products quicker than ever.
“Having been able to assist Neuronascent in this initial non-GMP project, we look forward to potentially having the opportunity to work with them on the next phase of the project that would involve the GMP production of API to support clinical trials.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance